Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: Do they play a role in ovarian carcinogenesis?

Journal of Veterinary Science

Volumn 11, Issue 4, 2010, Pages 291-297

  Kim, Ki Yon ^a   Park, Dong Wook ^a,c   Jeung, Eui Bae ^b   Choi, Kyung Chul ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Chungbuk National University   (South Korea)

^c Catholic Kwandong University   (South Korea)

Author keywords

BRCA; Conditional knockout; Ovarian cancer; p53; Tumor suppressor genes

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA2 PROTEIN, MOUSE; LOX PROTEIN, MOUSE; PROTEIN LYSINE 6 OXIDASE; PROTEIN P53; SCLEROPROTEIN;

ANIMAL; ARTICLE; CELL PROLIFERATION; CELL TRANSFORMATION; EPITHELIUM; FEMALE; GENE SILENCING; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; OVARY TUMOR; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIUM; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE SILENCING; MICE; MICE, KNOCKOUT; OVARIAN NEOPLASMS; PROTEIN-LYSINE 6-OXIDASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE; MUS;

EID: 78649504975     PISSN: 1229845X     EISSN: None     Source Type: Journal    
DOI: 10.4142/jvs.2010.11.4.291     Document Type: Article

References (37)

1. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 1998, 25, 281-304.
2. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001, 22, 255-288.
3. Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from brca1 heterozygotes. Cancer 2000, 89, 383-390.
4. Brodie SG, Deng CX. brca1-associated tumorigenesis: what have we learned from knockout mice? Trends Genet 2001, 17, S18-22.
5. Brodie SG, Xu X, Qiao W, Li WM, Cao L, Deng CX. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 2001, 20, 7514-7523.
6. Chan KY, Ozçelik H, Cheung AN, Ngan HY, Khoo US. Epigenetic factors controlling the brca1 and brca2 genes in sporadic ovarian cancer. Cancer Res 2002, 62, 4151-4156.
7. Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R. Stable interaction between the products of the brca1 and brca2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998, 2, 317-328.
8. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PCK. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 2001, 142, 2351-2360.
9. Clark-Knowles KV, Garson K, Jonkers J, Vanderhyden BC. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 2007, 313, 133-145.
10. Cressman VL, Backlund DC, Hicks EM, Gowen LC, Godfrey V, Koller BH. Mammary tumor formation in p53-and brca1-deficient mice. Cell Growth Differ 1999, 10, 1-10.
11. Deng CX, Brodie SG. Roles of brca1 and its interacting proteins. Bioessays 2000, 22, 728-737.
12. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003, 63, 3459-3463.
13. Frank TS, Critchfield GC. Identifying and managing hereditary risk of breast and ovarian cancer. Clin Perinatol 2001, 28, 395-406.
14. Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 1996, 12, 191-194.
15. Gretarsdottir S, Thorlacius S, Valgardsdottir R, Gudlaugsdottir S, Sigurdsson S, Steinarsdottir M, Jonasson JG, Anamthawat-Jonsson K, Eyfjörd JE. brca2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 1998, 58, 859-862.
16. Hedenfalk IA. Gene expression profiling of hereditary and sporadic ovarian cancers reveals unique brca1 and brca2 signatures. J Natl Cancer Inst 2002, 94, 960-961.
17. Herbst AL. The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol 1994, 170, 1099-1097.
18. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of brca1 and brca2 in ovarian cancer. J Natl Cancer Inst 2002, 94, 1396-1406.
19. Hosking L, Trowsdale J, Nicolai H, Solomon E, Foulkes W, Stamp G, Signer E, Jeffreys A. A somatic brca1 mutation in an ovarian tumour. Nat Genet 1995, 9, 343-344.
20. Koul A, Malander S, Loman N, Pejovic T, Heim S, Willen R, Johannsson O, Olsson H, Ridderheim M, Borg Å. brca1 and brca2 mutations in ovarian cancer: Covariation with specific cytogenetic features. Int J Gynecol Cancer 2000, 10, 289-295.
21. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, McGuffog L, Steele D, Devilee P, Klijn JG, Meijers-Heijboer H, Radice P, Pilotti S, Nevanlinna H, Butzow R, Sobol H, Jacquemier J, Lyonet DS, Neuhausen SL, Weber B, Wagner T, Winqvist R, Bignon YJ, Monti F, Schmitt F, Lenoir G, Seitz S, Hamman U, Pharoah P, Lane G, Ponder B, Bishop DT, Easton DF. Pathology of ovarian cancers in brca1 and brca2 carriers. Clin Cancer Res 2004, 10, 2473-2481.
22. Levine DA, Federici MG, Reuter VE, Boyd J. Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. Gynecol Oncol 2002, 85, 431-434.
23. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997, 11, 1226-1241.
24. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250, 1233-1238.
25. Marmorstein LY, Ouchi T, Aaronson SA. The brca2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA 1998, 95, 13869-13874.
26. Nicosia SV, Johnson JH. Surface morphology of ovarian mesothelium (surface epithelium) and of other pelvic and extrapelvic mesothelial sites in the rabbit. Int J Gynecol Pathol 1984, 3, 249-260.
27. Ramus SJ, Bobrow LG, Pharoah PD, Finnigan DS, Fishman A, Altaras M, Harrington PA, Gayther SA, Ponder BA, Friedman LS. Increased frequency of TP53 mutations in brca1 and brca2 ovarian tumours. Genes Chromosomes Cancer 1999, 25, 91-96.
28. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001, 22, 248-291.
29. Schlosshauer PW, Cohen CJ, Penault-Llorca F, Miranda CR, Bignon YJ, Dauplat J, Deligdisch L. Prophylactic oophorectomy: a morphologic and immunohistochemical study. Cancer 2003, 98, 2599-2606.
30. Scully R, Livingston DM. In search of the tumoursuppressor functions of brca1 and brca2. Nature 2000, 408, 429-432.
31. Sekine M, Nagata H, Tsuji S, Hirai Y, Fujimoto S, Hatae M, Kobayashi I, Fujii T, Nagata I, Ushijima K, Obata K, Suzuki M, Yoshinaga M, Umesaki N, Satoh S, Enomoto T, Motoyama S, Tanaka K. Mutational analysis of brca1 and brca2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of brca1 in Japanese population. Clin Cancer Res 2001, 7, 3144-3150.
32. Somasundaram K. Breast cancer gene 1 (brca1): role in cell cycle regulation and DNA repair--perhaps through transcription. J Cell Biochem 2003, 88, 1084-1091.
33. Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, Nishina H, Chuang T, Wakeham A, Itie A, Koo W, Billia P, Ho A, Fukumoto M, Hui CC, Mak TW. Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 1997, 11, 1242-1252.
34. Venkitaraman AR. Functions of brca1 and brca2 in the biological response to DNA damage. J Cell Sci 2001, 114, 3591-3598.
35. Venkitaraman AR. Cancer susceptibility and the functions of brca1 and brca2. Cell 2002, 108, 171-182.
36. Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, Deng CX, Ried T. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 2002, 21, 5097-5107.
37. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999, 22, 37-43.